Form 8-K Pacira Pharmaceuticals, For: Nov 01
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Pacira Pharmaceuticals (PCRX) PT Raised to $55 at Piper Jaffray
November 1, 2018 1:13 PM EDTPiper Jaffray analyst David Amsellem raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $55.00 (from $51.00) while maintaining a Overweight rating.
Amsellem cited a clear uptick in Exparel sales growth.
... More